Preparation of pegylated nanoliposomal oxaliplatin and investigation of its Efficacy on breast cancer cell lines MCF-7 and MDA-MB-231

Cancer is an important issue and cause of death among human breast cancer is the most common form of cancer types within women population in world. Oxaliplatin is a chemotherapy compound for treatment of cancer with side effects. Drug delivery system (DDS) and using of nanocarriers are known as one of the effective methods for cancer treatment. In this study, nanotechnology was applied to decrease drug side effects and enhancement of therapeutic index. In order to improve chemotherapeutic effective of Oxaliplatin, Nanoliposomation is used in pharmacological as beneficial developments. To achieve this results polymers, such as polyethylene glycol can reduce interactions with reticuloendothelial system (RES) and increase the circulation lifetime of the drug. In this work, pegylated nanoliposomal oxaliplatin was synthesized by reverse phase evaporation technique. The particle size and zeta potential were confirmed with dynamic light scattering (DLS). The results showed that the size of pegylated nanoliposomal oxaliplatin was147.7 nm. The zeta potential of pegylated nanoliposomal oxaliplatin assessed -20.5 mv. Zeta potential exhibits stability of pegylated nanoliposomal preparation. Morphology of liposomal nanodrug were examined by scanning electron microscopy (SEM). Entrapment efficiency of pegylated nanoliposomal oxalipltin was determinated 40.2%. Cytotoxicity effects of drug-loaded nanoparticles and pure drug were evaluated for MCF-7 and MDA-MB-231 breast cancer cell lines by MTT assay. The IC50 values for pegylated nanoliposomal oxaliplatin and pure oxaliplatin were assessed 0.1046 mg/ml and 0. 2307 mg/ml respectively for MCF-7 and 0.05125 mg/ml and 0.1023 mg/ml respectively for MDA-MB-231, hence the IC50 values of pegylated nanoliposomal oxaliplatin was estimated as 1/2 the IC50 of pure oxaliplatin. This indicated cytotoxicity of oxaliplatin-loaded nanoparticle was decreased in comparison to pure drug. Finally, in this investigation, effect of pegylated nanoliposomal oxaliplatin on MDA-MB-231 showed 2-times decrease of (in) IC50 value in comparison with MCF-7 at 96 h incubation.